ClinicalTrials.gg
RecruitingNCT06084299Updated Aug 19, 2025

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

A Phase 1 interventional study of Autologous Tumor Infiltrating Lymphocytes in Liver Cancer, sponsored by Zhiyong Huang. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-19.

Sponsored by Zhiyong Huang · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled May 2020, registered Oct 2023).
  • Started May 2020; still recruiting 6 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 310 studies in Liver Neoplasms with a site in China — 123 open to participants now, 135 under way, 7 of them phase 3. Liver Neoplasms · China.

Planned enrollment
213th of 236
16 · median 80
Started
2020
with 17 others
Phase 1
41 of 310
21 open now
Primary completion
2026-08
later than 61 of 134 live
Registered
210th of 310
by date

Among the 310 studies in Liver Neoplasms with a site in China, this one is the 213th largest by planned enrollment of the 236 interventional ones that give a count, is one of 18 that started in 2020, is one of 41 in phase 1, reaches primary completion later than 61 of the 134 other live ones, and was the 210th registered.

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

Browse Liver Neoplasms studies →

Open to participants now

123 of the 310 studies in Liver Neoplasms with a site in China are open now. Recruiting first, the newest first:

118 more — sign in →

All 123 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 244 Liver Neoplasms studies recruiting now, 137 (56%) set no upper age limit and 70 (29%) stop at 75 or younger; 14 take children under 18; 34 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 310 studies in Liver Neoplasms with a site in China, or all of them as a file.
02

Study summary

Single-arm, open-label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocytes (TIL) infusion followed by IL-2 after a non-myeloablative(NMA) lymphodepletion preparative regimen for the treatment of patients with advanced liver cancer.

Read the detailed description

This is an adoptive cell transfer therapy that utilizes an autologous TIL manufacturing process for the treatment of patients with advanced liver cancer. The cell transfer therapy used in this study involves patients receiving a non-myeloablative lymphodepletion preparative regimen, followed by i.v. infusion of autologous tumor-infiltrating lymphocytes followed by the administration of a regimen of IL-2.

03

Conditions studied

  • Liver Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects must be informed of the study before the test and voluntarily sign a written .
  • Age of the patients was between 18\~70 years
  • Eligible patients have proven advanced liver cancer
  • (ECOG) performance status was 0-1
  • lesions are confirmed by PET-CT, CT, MR and/or intraoperative exploration (more than 3, at least one accessible metastasis to procure for TILs)
  • Patients have at least one separate additional measurable tumour lesion according to version 1.1 standard.
  • The disease has progressed after at least two previous lines of standard treatment and there is no effective treatment option available
  • Adequate normal organ and marrow function were present, including ≥ 1×10\^9/L, leukocyte count ≥ 3×10\^9/L, count ≥ 75×10\^9/L, ≥ 80 g/L, and ALT ≤ 2× of , Serum creatinine ≤ 1.5× upper normal limits, Serum total ≤ 1.5× upper normal limits
  • Female subjects of childbearing age must have a negative urine or serum HCG test within 7 days before cell reinfusion
  • Provide at least one gram of fresh tumor tissue and 10ml of peripheral blood for whole exome sequencing and TIL isolation and culture.
  • Expected survival was at least 3 months
  • Child-Push liver function score grade is A within seven days before the cell reinfusion.

Exclusion criteria

Exclusion Criteria:

  • With previous or concurrent other active cancer (except carcinoma in situ that has been cured without onset within 5 years, or those that can be cured by adequate treatment)
  • Patients with to Central Nervous System or brain
  • Have received organ transplantation in the past
  • Received major liver surgery within 4 weeks before the first administration (except liver metastases ).
  • Received local treatment of the liver or other parts within 4 weeks before the first administration (transcatheter arterial chemoembolization [TACE], transcatheter arterial embolization [TAE], hepatic artery infusion [HAI], radiotherapy, radioembolization or ablation). Subjects are not eligible to participate in the study if the above-mentioned treatment is carried out between the last dose of sorafenib or oxaliplatin-containing regimen and the first study administration.
  • After CT angiography examination, there is severe arterial embolism or hepatic artery vascular variation.
  • or PT >= 5 UNL, or with bleeding evidence in two months or bleeding history in prior to the clinical study, no matter how serious it is
  • Active inflammation within 7 days after systemic antibiotics treatment
  • Subjects who have undergone major surgery or severe trauma such as laparotomy, thoracotomy, and laparoscopic organ removal within 4 weeks before enrollment.
  • Active coronary artery disease, serious or unstable angina pectoris, or newly diagnosed angina pectoris or myocardial infarction within 12 months prior to the clinical study
  • Thrombosis or embolism event within 12 months prior to the clinical study, such as cerebrovascular accident ( including ) or pulmonary embolism
  • Congestive heart failure of >= Class II
  • (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis (, defined as HBV-DNA ≥ 500 IU/ml C Hepatitis, defined as higher than the detection limit of the analytical method) or co-infection with hepatitis B and hepatitis C.
  • Presence of any active, known or suspected disease. Subjects in a stable state who do not require systemic therapy are allowed, such as: type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, and skin diseases that do not require systemic therapy (e.g., vitiligo, psoriasis disease and hair loss).
  • Any interstitial lung disease, noninfectious causes of lung inflammation, or uncontrolled systemic disease (e.g. diabetes, pulmonary fibrosis, or acute pneumonia)
  • Any adverse event of (Ver 5.0) grade 2 or higher induced by previous treatment, except anemia, hair loss, and skin pigmentation
  • Pregnant or lactating women or those who are positive in pregnancy test before 1st injection
  • The investigator believes that the subject has any clinical or laboratory abnormalities or compliance problems and is not suitable for participating in this clinical study.
  • With serious psychological or mental abnormalities
  • Joined other clinical trials in four weeks prior to this study
  • Patients who have a history of to cyclophosphamide and fludarabine.
  • Other researchers think that they are not suitable for enrollment.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Treatment (autologous tumor infiltrating lymphocytes)

    Post-NMA lymphodepletion, patients are infused with their autologous TIL followed by IL-2 administration.

    Biological: Autologous Tumor Infiltrating Lymphocytes

Interventions

06

What researchers measure

Primary outcomes

  1. Types and incidence of Dose-limiting toxicity (DLT) [Safety and Tolerability]

    Dose-limiting toxicity (DLT) will be collected and graded according to CTCAE v5.0

    Time frame: 1 month

  2. Types and incidence of adverse events (AEs) ,serious adverse events (SAEs) [Safety and Tolerability]

    AE will be collected and graded according to CTCAE v5.0

    Time frame: Up to 24 months

  3. Maximum tolerated dose [Safety and Tolerability]

    Evaluate the maximum tolerated dose of TILs in patients with advanced liver cancer

    Time frame: 1 month

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS will be calculated as the time from TIL infusion to disease progression or death from any cause (whichever occurs first) (RECIST v1.1).

    Time frame: 6 months

  2. Disease Control Rate (DCR)

    DCR will be calculated as the percentage of patients who achieved Stable Disease(SD) or better for more than 8 weeks (RECIST v1.1).

    Time frame: Up to 24 months

  3. Objective response rate (ORR)

    ORR will be calculated as the percentage of patients who achieved partial response (PR) or better (RECIST v1.1).

    Time frame: Up to 24 months

  4. Overall Survival (OS)

    Time from TIL infusion to time of death due to any cause

    Time frame: Up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Sarnaik A. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022 Dec;10(12):e005755. doi: 10.1136/jitc-2022-005755. PubMed 36600653 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2020 (actual). Primary completion is estimated for Aug 2026, 75 months after the start.

Of 48 non-industry phase 1 interventional studies under Liver Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 63. This study's planned 75 months is above that.

Counting every sponsor, half of 99 studies reached it within 49 months; a quarter within 32 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 3, 2023
First posted
Oct 16, 2023
StartActual
May 27, 2020
Primary completionEst.
Aug 30, 2026
CompletionEst.
Aug 30, 2026
Last update
Aug 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06084299
Lead sponsor
Zhiyong Huang
Collaborators
Wuhan Elongevity Technology Co., Ltd.
Responsible party
Zhiyong Huang (Professor, Tongji Hospital) — Sponsor-investigator
First posted
Oct 16, 2023
Start date
May 27, 2020
Primary completion
Aug 30, 2026 (estimated)
Completion
Aug 30, 2026 (estimated)
Last update
Aug 19, 2025

Study contacts

Tong Yuan
Contact
Zyhuang126@126.com
86-15071338542
Tian Xia
Contact
tianxia@hust.edu.cn
Zhiyong Huang
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lifileucel · Autologous Tumor Infiltrating Lymphocytes LN-145

Start the discussion